<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-91313" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>von Willebrand Factor</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Luke</surname>
            <given-names>Neeti P.</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Neeti Luke declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-91313.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Von Willebrand factor (vWF) mediates platelet adhesion to exposed subendothelial collagen at sites of vascular injury, facilitating the formation of primary hemostatic plugs. Von Willebrand disease (vWD), a bleeding disorder, arises from quantitative or qualitative defects in vWF. Replacement therapy with vWF is used to manage and treat vWD, especially for individuals refractory&#x000a0;to desmopressin. vWF is available in plasma-derived concentrates and, more recently, in recombinant form.</p>
        <p>This activity emphasizes the indications, contraindications, dosing, and monitoring associated with vWF replacement while helping clinicians understand the intricate pharmacology of vWF to tailor and administer treatment plans to individual patient needs. This activity allows clinicians to gain a deeper understanding of the key factors for the safe delivery of vWF, including its mechanism of action, adverse event profile, dosing, and relevant interactions, to effectively tailor treatment plans by collaborating with an interprofessional healthcare team in caring for patients with vWD.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients presenting with signs and symptoms suggestive of von Willebrand disease through comprehensive clinical assessment and appropriate diagnostic testing.</p></list-item><list-item><p>Implement evidence-based protocols for managing von Willebrand disease, including desmopressin and von Willebrand factor replacement therapy, tailored to patient-specific characteristics and treatment goals.</p></list-item><list-item><p>Select appropriate von Willebrand factor replacement products, considering patient factors such as age, comorbidities, and response history to previous treatments.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team to develop comprehensive care plans that improve outcomes and treatment efficacy for patients benefiting from von Willebrand factor therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=91313&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=91313">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-91313.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Von Willebrand disease (vWD) is a common bleeding disorder caused by quantitative or qualitative defects in the von Willebrand factor (vWF). The clinical management of vWD has evolved over the past few decades, but the condition still poses diagnostic and therapeutic challenges. Currently, desmopressin is the treatment of choice for type 1 vWD because it corrects factor VIII (FVIII) and vWF levels.<xref ref-type="bibr" rid="article-91313.r1">[1]</xref> However, desmopressin is ineffective in patients with type 3 vWD and some forms of type 1 and type 2 vWD. For these patients, replacement therapy containing FVIII and vWF concentrates is the mainstay of treatment.<xref ref-type="bibr" rid="article-91313.r2">[2]</xref>&#x000a0;</p>
        <p>Replacement therapy in managing vWD has advanced over the past few years. Initially, cryoprecipitate was the most commonly used form of replacement therapy, but it is no longer recommended in the United States or Europe. Since then, replacement forms of vWF have progressed from crude plasma protein preparations to plasma concentrate mixtures that contain both vWF and FVIII. More recently, vWF replacement therapy has transitioned from plasma-derived concentrates of vWF/FVIII mixtures with a higher FVIII content to recombinant vWF (rvWF) with a much lower concentration of FVIII.<xref ref-type="bibr" rid="article-91313.r3">[3]</xref> Earlier concentrates had high FVIII levels with vWF:ristocetin (vWF:RCo) cofactor to FVIII ratios less than or equal to 1, whereas more recent rvWF has lower FVIII levels and vWF:RCo/FVIII ratios greater than 10.<xref ref-type="bibr" rid="article-91313.r4">[4]</xref></p>
        <p>Desmopressin is the first-line therapy for managing acute bleeding and for prophylaxis before minor surgeries in patients with vWD. However, desmopressin has therapeutic limitations, particularly tachyphylaxis. Data correlating the biological response to desmopressin with efficacy are limited, and metabolic adverse events such as hyponatremia are also a concern. Physicians may use vWF replacement therapy for treating certain high-risk individuals, especially those with vWD types that respond poorly to desmopressin. Desmopressin is contraindicated in patients with vWD types 2B and 3. Currently, guidelines for using replacement therapy in managing vWD have not been established.</p>
        <p>The most common indications for&#x000a0;using vWF in clinical practice are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with vWD with&#x000a0;minimal to no desmopressin response.<xref ref-type="bibr" rid="article-91313.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with vWD and undergoing major surgery and procedures with high bleeding risk.<xref ref-type="bibr" rid="article-91313.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with type 3 vWD and typically having limited or no response to&#x000a0;desmopressin.<xref ref-type="bibr" rid="article-91313.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with certain type 2 vWD variants:
<list list-type="bullet"><list-item><p>Subtypes 2B and 2M, where&#x000a0;patients have altered vWF-dependent platelet adhesion.<xref ref-type="bibr" rid="article-91313.r8">[8]</xref></p></list-item><list-item><p>Subtype 2A, where high-molecular-weight vWF multimer deficiencies or abnormalities are present.</p></list-item><list-item><p>Subtype 2N, where affinity for FVIII is reduced.<xref ref-type="bibr" rid="article-91313.r9">[9]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Patients with severe type 1 vWD (vWF:RCo activity&#x000a0;&#x0003c;10 IU/dL / FVIII activity&#x000a0;&#x0003c;20 IU/dL).</p>
          </list-item>
          <list-item>
            <p>Patients with acquired von Willebrand syndrome (avWS) and requiring prophylaxis before major surgical procedures.</p>
          </list-item>
          <list-item>
            <p>Patients with monoclonal gammopathy of unknown significance (MGUS) who have failed to respond to&#x000a0;desmopressin. vWF replacement is combined with FVIII in patients with MGUS.</p>
          </list-item>
        </list>
        <p>vWF is used along with FVIII concentrates in children with hemophilia A who have previously failed immune tolerance induction with pure recombinant FVIII (rFVIII) alone. Immune tolerance induction protocols are particularly recommended for children with hemophilia A who have developed an inhibitor against FVIII, which is one of the most severe complications of substitutive treatment in hemophilia.</p>
        <p>Some clinicians prefer vWF replacement therapy in patients with vWD undergoing major surgery and in high-risk populations, including pediatric patients aged 2 or younger, older individuals with extensive comorbidities, and people at high risk for thrombosis (eg, due to old age or cancer or orthopedic surgery). Secondary prophylaxis may be useful in patients with type 3 vWD with concomitant low FVIII levels who experience frequent hemarthrosis, frequent and chronic epistaxis, chronic arthropathy, and recurrent gastrointestinal bleeding.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>RvWF is approved by the US Food and Drug Administration (FDA) for use in&#x000a0;individuals aged 18 and older with vWD in the following settings:</p>
        <list list-type="bullet">
          <list-item>
            <p>Management of bleeding during surgical procedures.</p>
          </list-item>
          <list-item>
            <p>Treatment and control of acute bleeding episodes.</p>
          </list-item>
          <list-item>
            <p>Routine prophylaxis to decrease the frequency of bleeding episodes in patients with severe type 3 vWD who are on on-demand therapy.<xref ref-type="bibr" rid="article-91313.r10">[10]</xref><xref ref-type="bibr" rid="article-91313.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>In a randomized controlled trial, prophylactic use of rvWF showed significant efficacy by markedly reducing treated spontaneous bleeding events in adults with severe vWD while maintaining a favorable safety profile.<xref ref-type="bibr" rid="article-91313.r12">[12]</xref> Prophylactic rvWF also reduced treated spontaneous bleeding rates in patients with type 3 vWD who had previously received on-demand vWF therapy, and it maintained comparable hemostatic efficacy in those transitioning from plasma-derived vWF prophylaxis to rvWF prophylaxis.<xref ref-type="bibr" rid="article-91313.r13">[13]</xref></p>
      </sec>
      <sec id="article-91313.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>vWF is an adhesive glycoprotein multimer synthesized by endothelial cells in Weibel-Palade bodies and megakaryocytes in &#x003b1;-granules.&#x000a0;The factor plays various essential functions for&#x000a0;both primary and secondary hemostasis.&#x000a0;The primary function of vWF is to facilitate platelet adhesion to the subendothelium when exposed to vascular injury.&#x000a0;The factor&#x000a0;also interacts with fibrinogen in platelet-to-platelet interactions, promoting thrombus growth and stabilization. Additionally, vWF serves as a carrier protein for FVIII in plasma, protecting the latter from proteolytic degradation.<xref ref-type="bibr" rid="article-91313.r14">[14]</xref></p>
        <p>These pleiotropic functions of vWF can be assessed using various laboratory assays. Deficiency or abnormalities in vWF lead to vWD, the most common autosomal inherited bleeding disorder. Replacement therapy in vWD addresses the dual defect of hemostasis&#x02014;abnormal platelet adhesion aggregation and aberrant intrinsic coagulation caused by low and unstable circulating FVIII. Replacing deficient or abnormal vWF and correcting low FVIII levels are equally essential for restoring normal hemostasis in patients with vWD. RvWF is produced without human plasma proteins, thereby eliminating the risk of transmitting blood-borne pathogens and preventing any effects from copurifying plasma proteins.<xref ref-type="bibr" rid="article-91313.r15">[15]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>RvWF administered alone raises endogenous FVIII levels to above 40% within 6 hours. This characteristic is crucial for rvWF's utility as it minimizes the requirement for repeated dosing and reduces the risk of elevated FVIII levels, thereby lowering the potential for thrombotic complications. RvWF undergoes cleavage by ADAMTS13 into smaller multimers, and infused rvWF exhibits a half-life approaching 22 hours.<xref ref-type="bibr" rid="article-91313.r16">[16]</xref><xref ref-type="bibr" rid="article-91313.r17">[17]</xref></p>
      </sec>
      <sec id="article-91313.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Different human mixtures of vWF/FVIII products are available for replacement therapy. These concentrates were originally introduced in clinical practice for hemophilia management.&#x000a0;The mixtures of vWF/FVIII concentrates available are plasma-derived and&#x000a0;have variable FVIII quantities. In December 2015, the FDA also approved an rvWF concentrate for use in adult patients with vWD who were experiencing bleeding episodes.</p>
        <p>The vWF:RCo activity is expressed in IU. Notably, 1 IU corresponds to a vWF:RCo level present in 1 mL of human plasma concentrate. An infusion of 1 IU/kg of vWF:RCo raises the plasma level of vWF:RCo by around 1.5 IU/dL. Generally, an initial plasma vWF concentrate dose of 40 to 60 IU (expressed as units of&#x000a0;Rco, vWF:RCo) per kg per body weight is given to obtain plasma levels of 50 to 100 IU/dL.&#x000a0;Subsequent doses depend on the clinical response,&#x000a0;with 20 to 40 IU/Kg body weight every 12 hours generally sustaining plasma concentrations within 50% to 100% in patients without a shortened vWF half-life.</p>
        <p>
<bold>Available Strengths</bold>
</p>
        <p>Various formulations of lyophilized powder for intravenous solution reconstitution containing&#x000a0;FVIII (antihemophilic factor) with vWF complex are available in the following dosages&#x02014;250 IU, 450 IU FVIII/450 vWF, 500 IU, 900 IU FVIII/900 vWF, 1000 IU, and 1500 IU. RvWF is also available in single-dose vials containing 650 or 1300 IU vWF:RCo. Notably, available formulations are not equivalent and should not be used interchangeably.</p>
        <p>
<bold>Adult Dosages</bold>
</p>
        <p>Patients with avWS who have vWF inhibitors require higher and more frequent doses to achieve desired vWF levels. Although rare, continuous vWF infusion&#x000a0;has been used in patients who cannot maintain adequate vWF levels with intermittent infusions and do not respond clinically. The dosages range between 2 and 15 IU/kg/h.<xref ref-type="bibr" rid="article-91313.r18">[18]</xref></p>
        <p>The recommended general dose range varies from 30&#x000a0;to 100 vWF:RCo units/kg. However, the dosage can be adjusted based on the patient's residual activity, the presence of autoantibodies and inhibitors, and the severity of bleeding.</p>
        <p>The dose given also depends&#x000a0;on&#x000a0;bleeding severity, as described below:</p>
        <list list-type="bullet">
          <list-item>
            <p>Spontaneous bleeding episodes: Daily dose or a single dose of 30&#x000a0;to 60 IU/kg of vWF to maintain FVIII coagulant (FVIII:C) levels greater than 30 U/dL or until bleeding stops (generally 2-4 days).</p>
          </list-item>
          <list-item>
            <p>Major surgery: Daily doses of 50&#x000a0;to 60 IU/kg of&#x000a0;vWF to achieve preoperative levels FVIII:C and&#x000a0;vWF:RCo levels of 80&#x000a0;to 100 U/dL until 36 hours postoperatively, followed by levels greater than 50 U/dL until complete&#x000a0;recovery (usually 5-10 days).</p>
          </list-item>
          <list-item>
            <p>Minor surgery: Daily doses of 30&#x000a0;to 60 IU/kg of vWF to obtain FVIII:C levels greater than 30 U/dL until healing is complete (2-4 days).</p>
          </list-item>
          <list-item>
            <p>Dental extraction or invasive procedures: A single dose of 30 IU/kg of vWF to obtain FVIII:C levels greater than 50 U/dL for 12&#x000a0;to 24 hours.</p>
          </list-item>
          <list-item>
            <p>Delivery and postpartum: Daily doses of 50 IU/kg of vWF to obtain FVIII:C levels greater than 50 U/dL for 3&#x000a0;to 4 days.</p>
          </list-item>
        </list>
        <p>Limited data are available&#x000a0;on rvWF in avWS.&#x000a0;Theoretically, rvWF has more advantages due to its longer half-life and lack of FVIII content, particularly in patients with high FVIII levels and at high risk for thrombosis. The usual starting dose is 80 mcg/kg intravenously.<xref ref-type="bibr" rid="article-91313.r19">[19]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> The product labeling does not include any dosage adjustments.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;The product labeling does not include any dosage adjustments.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Pregnant women with vWD are at increased risk of postpartum hemorrhage if untreated, underscoring the need for early treatment planning. Invasive delivery methods such as ventouse or rotational forceps should be avoided due to the potential risk of neonatal bleeding. Testing for desmopressin responsiveness before pregnancy is recommended for women with basal FVIII and vWF levels below 30 U/dL. During pregnancy, monitoring FVIII and&#x000a0;vWF levels in the&#x000a0;3rd trimester is crucial, aiming for levels above 50 U/dL to minimize bleeding risk. Treatment strategies should be tailored according to the type of vWD, emphasizing close management to maintain hemostasis throughout pregnancy and postpartum.<xref ref-type="bibr" rid="article-91313.r20">[20]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Clinical data on the use of vWF&#x000a0;during breastfeeding are unavailable. Given its large protein structure,&#x000a0;vWF may be present in minimal amounts in breast milk and is likely destroyed in the infant's gastrointestinal tract, making absorption unlikely. Therefore, caution is advised when considering vWF therapy during breastfeeding, particularly in newborns or preterm infants.<xref ref-type="bibr" rid="article-91313.r21">[21]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The safety and effectiveness of rVWF in individuals aged 18 or younger have not been established. The FVIII/vWF&#x000a0;complex is utilized for the treatment of both hemophilia A and vWD.</p>
        <p><bold>Older patients:</bold> Studies of rVWF did not include sufficient subjects aged 65 and older to determine whether their response differs from that of younger subjects.</p>
      </sec>
      <sec id="article-91313.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Despite extensive screening protocols for detecting viruses and other infections, the risk of transmission of various blood-borne infections during vWF replacement cannot be entirely excluded.<xref ref-type="bibr" rid="article-91313.r22">[22]</xref>&#x000a0;Studies have reported rare adverse effects in a small number of subjects receiving replacement therapy with vWF, including mild infusion site paresthesia, moderate dysgeusia, moderate tachycardia, mild generalized pruritus, and hot flushes. A few severe adverse events were noted, such as mild T-wave inversion on electrocardiography, chest discomfort, and increased heart rate. In addition, alloantibodies, such as anti&#x02013;vWF-binding antibodies, may also develop. FVIII neutralizing antibodies were noted postreplacement therapy.<xref ref-type="bibr" rid="article-91313.r23">[23]</xref></p>
        <p>FVIII can accumulate in plasma when multiple closely spaced infusions are administered for severe bleeding or prophylactically before major surgeries. This accumulation results from exogenous FVIII infused with the concentrate mixture and an increase in endogenous FVIII synthesized by the infused vWF. Persistent high levels of FVIII may heighten the risk of postoperative thrombotic events, such as deep vein thrombosis.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>According to the FDA-approved labeling and recent literature reviews, no drug interactions had been reported at the time this article was written.</p>
      </sec>
      <sec id="article-91313.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Some patients with type 3 vWD can develop alloantibodies after multiple transfusions. Infusion of vWF concentrates in these patients is ineffective and can cause life-threatening postinfusion anaphylaxis due to the formation of immune complexes.<xref ref-type="bibr" rid="article-91313.r24">[24]</xref>&#x000a0;Therefore, vWF should be avoided in these patients, and rFVIII should be used alone and administered at high doses by continuous intravenous infusion, considering the short half-life of FVIII without its vWF carrier.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Thromboembolism:</bold> In patients at high risk for thrombotic events, such as those with advanced age, cancer, or undergoing orthopedic surgery, multiple vWF doses should be administered with caution due to the increased risk of arterial thrombosis. Venous thromboembolic complications have been noted in some patients with vWD, which can be attributed to sustained high levels of FVIII from multiple closely spaced infusions of FVIII/vWF concentrates. Low-molecular-weight heparin can be used prophylactically in such patients. vWF should be used cautiously in patients at high risk of venous thrombosis.</p>
        <p><bold>Transmission of infectious agents:</bold> Some vWF products are derived from human blood, posing a risk of transmitting infectious diseases, including variant Creutzfeldt-Jakob disease and Parvovirus B19. Despite measures such as donor screening and virus testing during manufacturing, complete elimination of transmission risk cannot be assured.</p>
      </sec>
      <sec id="article-91313.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Close monitoring of clinical response and vWF&#x000a0;activity measurements is required for dosage adjustments and intervals. The standard parameters essential to monitor are FVIII:C, vWF antigen (vWF Ag), and vWF:RCo. The FVIII:C&#x000a0;and vWF:RCo assays are primarily required to monitor replacement therapy. The general goal is to sustain the activity of FVIII and vWF (generally measured as vWF:RCo) between 50%&#x000a0;and 100% for 3 to 14 days in patients with significant bleeding episodes or before major surgery. Notably, the half-life of infused vWF is short in avWS, especially&#x000a0;in patients with avWS associated with inhibitors or MGUS.<xref ref-type="bibr" rid="article-91313.r25">[25]</xref></p>
        <p>Levels of vWF:RCo and FVIII activity must be obtained&#x000a0;immediately before and shortly after the infusion to determine the half-life of the infused products. Levels should then be measured at 4, 8, and 12 hours after the first infusion to obtain half-life information, with more spaced-out testing performed subsequently (every 12 to 24 hours), depending on the patient's clinical status and response. In major surgeries, plasma levels of FVIII:C and vWF:RCo must be obtained initially every 12 hours on the day of surgery and subsequently every 24 hours.</p>
        <p>Monitoring FVIII activity is crucial to ensure it stays below 200 IU/dL, as high FVIII levels increase the risk of thrombosis. The half-life of FVIII:C postinfusion is approximately double that of vWF Ag (20-24 hours compared to 10-14 hours), attributed to&#x000a0;the endogenous increase of FVIII levels, which is stabilized by the additionally infused exogenous vWF.&#x000a0;Patients who cannot maintain adequate factor levels&#x000a0;with intermittent infusions and who fail to respond clinically may receive continuous factor infusion, necessitating closer monitoring.<xref ref-type="bibr" rid="article-91313.r26">[26]</xref></p>
        <p>The 2021 guidelines from the American Society of Hematology (ASH), International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH) on managing vWD recommend targeting both FVIII and vWF activity levels of greater than or equal to 0.50 IU/mL for at least 3 days following major surgery. The guidelines advise against using only FVIII levels of greater than or equal to 0.50 IU/mL as a target for this period.<xref ref-type="bibr" rid="article-91313.r27">[27]</xref></p>
      </sec>
      <sec id="article-91313.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Data show that vFW:rFVIII is generally safe and effective in patients with severe bleeding in various clinical settings.&#x000a0;Studies have not detected inhibitors for vWF:RCo, vWF Ag, vWF collagen binding, and FVIII:C developed after repeated treatment.&#x000a0;However,&#x000a0;multiple infusions can lead to the development of antibodies against FVIII:vWF in patients with severe homozygous-like vWD.</p>
      </sec>
      <sec id="article-91313.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>One of the most frequently encountered inherited bleeding disorders is vWD, with a prevalence of 1 in 1000 individuals. The clinical management of vWD is complex, and no clear, standardized guidelines for biological therapies and treatment protocols are universally followed. Desmopressin remains the treatment of choice for patients with type 1 vWD. However, this agent is ineffective in patients with type 3 and severe forms of type 1 and 2 vWD. Thus, replacement therapy with plasma concentrates containing FVIII and vWF is the mainstay of treatment in these more complex cases. Clinicians also prefer replacement therapy in certain high-risk populations.&#x000a0;</p>
        <p>Replacement therapy with vWF has evolved from crude plasma protein preparations to plasma-derived concentrates containing vWF and FVIII mixtures. However, the varying contents of vWF and FVIII have contributed to the lack of a systematic approach to replacement therapy in vWD. Recently, the treatment of vWD has advanced from plasma-derived vWF/FVIII concentrates (vWF:RCo/FVIII ratios &#x02264;1) to rvWF with very low levels of FVIII (vWF:RCo/FVIII ratios &#x0003e;10).</p>
        <p>The management of vWD aims to correct the dual defect of hemostasis&#x02014;abnormal coagulation reflected by low levels of FVIII and abnormal platelet adhesion, indicated by prolonged bleeding time. Adequate restoration of hemostasis requires correcting deficient or dysfunctional vWF and low FVIII levels. Hematologists should be consulted for vWD and hemophilia management. Collaboration between&#x000a0;surgeons and hematologists is necessary for optimal outcomes in patients undergoing surgery. Pharmacists are responsible for verifying dosing, and nurses should monitor for any transfusion reactions.</p>
        <p>Although the treatment of vWD has evolved tremendously, it still poses&#x000a0;significant management challenges. Effective, individualized, and standardized treatment options are urgently needed to prevent dangerous acute bleeding episodes and improve the quality of life for patients with vWD. An interprofessional team approach and open communication between clinicians, including medical doctors, doctors of osteopathic medicine, nurse practitioners, physician assistants, and hematologists, are essential for optimizing outcomes associated with vWF therapy.</p>
      </sec>
      <sec id="article-91313.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=91313&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=91313">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/91313/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=91313">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-91313.s11">
        <title>References</title>
        <ref id="article-91313.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>VH</given-names>
              </name>
            </person-group>
            <article-title>Advances in the diagnosis and treatment of Von Willebrand disease.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Nov</month>
            <day>30</day>
            <volume>130</volume>
            <issue>22</issue>
            <fpage>2386</fpage>
            <page-range>2386-2391</page-range>
            <pub-id pub-id-type="pmid">29187375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klaassen</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Halton</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and treatment of von Willebrand disease in children.</article-title>
            <source>Paediatr Child Health</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>245</fpage>
            <page-range>245-9</page-range>
            <pub-id pub-id-type="pmid">20046298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mannucci</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>New therapies for von Willebrand disease.</article-title>
            <source>Blood Adv</source>
            <year>2019</year>
            <month>Nov</month>
            <day>12</day>
            <volume>3</volume>
            <issue>21</issue>
            <fpage>3481</fpage>
            <page-range>3481-3487</page-range>
            <pub-id pub-id-type="pmid">31714963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peyvandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kouides</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Turecek</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Dow</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Berntorp</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.</article-title>
            <source>Blood Rev</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>38</volume>
            <fpage>100572</fpage>
            <pub-id pub-id-type="pmid">31229334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castaman</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment of von Willebrand disease with FVIII/VWF concentrates.</article-title>
            <source>Blood Transfus</source>
            <year>2011</year>
            <month>May</month>
            <volume>9 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>s9</fpage>
            <page-range>s9-13</page-range>
            <pub-id pub-id-type="pmid">21839030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michiels</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>van Vliet</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Berneman</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gadisseur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van der Planken</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schroyens</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>van der Velden</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.</article-title>
            <source>Clin Appl Thromb Hemost</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-34</page-range>
            <pub-id pub-id-type="pmid">17164493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lillicrap</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>BA</given-names>
              </name>
              <collab>Association of Hemophilia Clinic Directors of Canada</collab>
            </person-group>
            <article-title>Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.</article-title>
            <source>Thromb Haemost</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>224</fpage>
            <page-range>224-30</page-range>
            <pub-id pub-id-type="pmid">11858481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michiels</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>van Vliet</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Berneman</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Schroyens</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gadisseur</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.</article-title>
            <source>Acta Haematol</source>
            <year>2009</year>
            <volume>121</volume>
            <issue>2-3</issue>
            <fpage>167</fpage>
            <page-range>167-76</page-range>
            <pub-id pub-id-type="pmid">19506363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castaman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Linari</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2016</year>
            <volume>12</volume>
            <fpage>1029</fpage>
            <page-range>1029-37</page-range>
            <pub-id pub-id-type="pmid">27445481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hancock</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Escobar</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>157</fpage>
            <page-range>157-161</page-range>
            <pub-id pub-id-type="pmid">36861346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leebeek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Casari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lillicrap</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of von Willebrand disease in 2024 and beyond.</article-title>
            <source>Haemophilia</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>30 Suppl 3</volume>
            <fpage>103</fpage>
            <page-range>103-111</page-range>
            <pub-id pub-id-type="pmid">38481079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leebeek</surname>
                <given-names>FWG</given-names>
              </name>
              <name>
                <surname>Peyvandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Escobar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tiede</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castaman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wynn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baptista</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mellg&#x000e5;rd</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>&#x000d6;zen</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.</article-title>
            <source>Blood</source>
            <year>2022</year>
            <month>Jul</month>
            <day>14</day>
            <volume>140</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-98</page-range>
            <pub-id pub-id-type="pmid">35439298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leebeek</surname>
                <given-names>FWG</given-names>
              </name>
              <name>
                <surname>Peyvandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tiede</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castaman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Escobar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Z&#x000fc;lfikar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Susen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miesbach</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000d6;zen</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial.</article-title>
            <source>Eur J Haematol</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>111</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-40</page-range>
            <pub-id pub-id-type="pmid">36823994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Werner</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>von Willebrand disease in children and adolescents.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>683</fpage>
            <page-range>683-707</page-range>
            <pub-id pub-id-type="pmid">8649905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gritsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schrenk</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weinhappl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mellg&#x000e5;rd</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ewenstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Turecek</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease.</article-title>
            <source>J Blood Med</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>649</fpage>
            <page-range>649-662</page-range>
            <pub-id pub-id-type="pmid">36405429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mannucci</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Kempton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Millar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Romond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Birschmann</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ragni</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Klamroth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Engl</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Turecek</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Suiter</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Ewenstein</surname>
                <given-names>BM</given-names>
              </name>
              <collab>rVWF Ad Hoc Study Group</collab>
            </person-group>
            <article-title>Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Aug</month>
            <day>01</day>
            <volume>122</volume>
            <issue>5</issue>
            <fpage>648</fpage>
            <page-range>648-57</page-range>
            <pub-id pub-id-type="pmid">23777763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metjian</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>rVWF: treatment finally reaches the modern age.</article-title>
            <source>Blood</source>
            <year>2015</year>
            <month>Oct</month>
            <day>22</day>
            <volume>126</volume>
            <issue>17</issue>
            <fpage>1975</fpage>
            <page-range>1975-6</page-range>
            <pub-id pub-id-type="pmid">26494919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Lillicrap</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mannucci</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Alloantibodies in von Willebrand disease.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Aug</month>
            <day>01</day>
            <volume>122</volume>
            <issue>5</issue>
            <fpage>636</fpage>
            <page-range>636-40</page-range>
            <pub-id pub-id-type="pmid">23297130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Castaman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Windyga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kouides</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ragni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leebeek</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Obermann-Slupetzky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fritsch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pavlova</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Presch</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ewenstein</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.</article-title>
            <source>Blood</source>
            <year>2015</year>
            <month>Oct</month>
            <day>22</day>
            <volume>126</volume>
            <issue>17</issue>
            <fpage>2038</fpage>
            <page-range>2038-46</page-range>
            <pub-id pub-id-type="pmid">26239086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castaman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy and delivery in women with von Willebrand disease.</article-title>
            <source>Eur J Haematol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>73</fpage>
            <page-range>73-79</page-range>
            <pub-id pub-id-type="pmid">31107984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <chapter-title>Von Willebrand Factor</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>12</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">29999950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuohy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Litt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alikhan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment of patients with von Willebrand disease.</article-title>
            <source>J Blood Med</source>
            <year>2011</year>
            <volume>2</volume>
            <fpage>49</fpage>
            <page-range>49-57</page-range>
            <pub-id pub-id-type="pmid">22287863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyrle</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Minar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hirschl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bialonczyk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Weltermann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Speiser</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lechner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eichinger</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>Aug</month>
            <day>17</day>
            <volume>343</volume>
            <issue>7</issue>
            <fpage>457</fpage>
            <page-range>457-62</page-range>
            <pub-id pub-id-type="pmid">10950667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergamaschini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mannucci</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Federici</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guzzoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agostoni</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.</article-title>
            <source>J Lab Clin Med</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>125</volume>
            <issue>3</issue>
            <fpage>348</fpage>
            <page-range>348-55</page-range>
            <pub-id pub-id-type="pmid">7897302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fressinaud</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Veyradier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sigaud</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boyer-Neumann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Le Boterff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates.</article-title>
            <source>Br J Haematol</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>106</volume>
            <issue>3</issue>
            <fpage>777</fpage>
            <page-range>777-83</page-range>
            <pub-id pub-id-type="pmid">10468873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peyvandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mamaev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Stasyshyn</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Timofeeva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Kavakli</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Castaman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sytkowski</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.</article-title>
            <source>J Thromb Haemost</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-62</page-range>
            <pub-id pub-id-type="pmid">30362288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91313.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connell</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Brignardello-Petersen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abdul-Kadir</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arapshian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Couper</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grow</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kouides</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Laffan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lavin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leebeek</surname>
                <given-names>FWG</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ozelo</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Tosetto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weyand</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Kalot</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Husainat</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.</article-title>
            <source>Blood Adv</source>
            <year>2021</year>
            <month>Jan</month>
            <day>12</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>301</fpage>
            <page-range>301-325</page-range>
            <pub-id pub-id-type="pmid">33570647</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
